Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial
ActRII inhibitors such as bimagrumab have the strongest body-composition data, but consistent functional benefits and long-term safety in diverse populations are lacking
However, what we know so far is that the greatest utilization of these therapies have been observed in predominantly wealthy communities, which have comparatively lower rates of obesity and associated cardiometabolic conditions. Most of the data on these therapies thus far has been driven by clinical trials, which do not account for disruptions in medication adherence that often occur among everyday people
This causes inflammation through the entire body
PlexusDx's Precision Peptide Genetic Test ($99 add-on) analyzes variants like GLP1R rs6923761 and GIPR rs1800437 to identify how your genetics influence semaglutide response across 14 metabolic pathways
The high-protein, portion-controlled approach supports muscle preservation and minimizes side effects common to all GLP-1 medications
